Frank Hsu
Directeur/Bestuurslid bij Karin Grunebaum Cancer Research Foundation
Profiel
Frank J.
Hsu is a trustee at Karin Grunebaum Cancer Research Foundation.
He was a Senior Director-Medical at Genzyme Corp.
from 2002 to 2012, and Director-Immunology Research Programs at Yale Cancer Center from 1996 to 2002.
He was also a Researcher at Stanford University from 1990 to 1996.
From 2012 to 2013, he served as the Chief Medical Officer at Zyngenia, Inc. He was the Vice President & Head-Oncology at Immune Design Corp.
from 2014 to 2018.
Currently, he is the Chief Medical Officer at Oncternal Therapeutics, Inc. and the Chief Marketing Officer at Apexigen, Inc. Hsu received his undergraduate degree from Stanford University and his doctorate from Harvard Medical School.
Actieve functies van Frank Hsu
Bedrijven | Functie | Begin |
---|---|---|
Karin Grunebaum Cancer Research Foundation | Directeur/Bestuurslid | - |
Eerdere bekende functies van Frank Hsu
Bedrijven | Functie | Einde |
---|---|---|
APEXIGEN, INC. | Hoofd Techniek/Wetenschap/O&O | 23-08-2023 |
IMMUNE DESIGN CORP | Corporate Officer/Principal | 01-01-2018 |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Hoofd Techniek/Wetenschap/O&O | 01-06-2013 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2012 |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 01-01-2002 |
Opleiding van Frank Hsu
Stanford University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
APEXIGEN, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zyngenia, Inc.
Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Retail Trade |
Yale Cancer Center
Yale Cancer Center Hospital/Nursing ManagementHealth Services Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT. | Health Services |
Immune Design Corp.
Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Karin Grunebaum Cancer Research Foundation |